Following positive results of the REACH-2 clinical trial in graft-versus-host disease (GVHD), Ruxolitinib, a JAK1/2 inhibitor, obtained FDA approval, and it is now considered the gold standard in glucocorticoid-refractory acute GVHD treatment (141). Here, JAK1 is linked to graft versus host disease.